Amal Therapeutics awarded with CTI Start-up Label

Geneva, Switzerland, November 26, 2014 – Amal Therapeutics, a Geneva based start-up biotech company developing and progressing therapeutic vaccines in oncology, announced today that it received the CTI Start-up Label from Swiss Commission for Technology and Innovation (CTI). This recognition of a promising development places Amal Therapeutics into the selective group of CTI certified Swiss […]

Amal Therapeutics receives EU funding for the development of a new glioblastoma vaccine

24 July 2014, Geneva, Switzerland and Archamps, France – Amal Therapeutics, a Swiss biotech start-up company, and TransCure bioServices, a French preclinical contract research organization, have obtained a European Eurostars Programme grant, for a total of 1.07 million Euro. This award winning project, named HuVac, aims to use enhanced humanized immune system mouse models for […]

Amal Therapeutics announces the appointment of Dr Johanna Holldack as Chairman

Geneva/Berlin, 30th June 2014. Amal Therapeutics SA, a Swiss and German‐based company focusing on the development of therapeutic cancer vaccines, announced today the appointment of Dr Johanna Holldack as chairman of the board. Dr Holldack brings over 20 years experience in Biotechnology and Drug Development. View PDF

Amal Therapeutics raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds

Geneva/Berlin/Ingelheim/Bonn, 20th February 2014. Amal Therapeutics SA, a Swiss and German-­based company focusing on the development of therapeutic cancer vaccines, announced today that it has closed its seed financing round. The funds will be used to consolidate the cell-­penetrating peptide based technology platform and progress the first vaccine candidate up to pre-­clinical development. The investment […]